# An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

> **NCT06169397** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Xentria, Inc.** · enrollment: 94 (estimated)

## Conditions studied

- Pulmonary Sarcoidosis

## Interventions

- **DRUG:** XTMAB-16

## Key facts

- **NCT ID:** NCT06169397
- **Lead sponsor:** Xentria, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-03-01
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06169397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06169397, "An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06169397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*